Although Komai et al. reported a favorable prognosis for the PRCC-TFE3 gene fusion and poor oncological outcomes for the ASPL-TFE3 gene fusion [7], Argani et al. reported two cases of the PRCC-TFE3 gene fusion with metastatic disease [29]. This evidence concerns the gene ASPSCR1 and metastatic neoplasm.